Literature DB >> 25224652

Reversible covalent inhibition of eEF-2K by carbonitriles.

Ashwini K Devkota1, Ramakrishna Edupuganti, Chunli Yan, Yue Shi, Jiney Jose, Qiantao Wang, Tamer S Kaoud, Eun Jeong Cho, Pengyu Ren, Kevin N Dalby.   

Abstract

eEF-2K is a potential target for treating cancer. However, potent specific inhibitors for this enzyme are lacking. Previously, we identified 2,6-diamino-4-(2-fluorophenyl)-4H-thiopyran-3,5-dicarbonitrile (DFTD) as an inhibitor of eEF-2K. Here we describe its mechanism of action against eEF-2K, on the basis of kinetic, mutational, and docking studies, and use chemoinformatic approaches to identify a similar class of carbonitrile-containing compounds that exhibit the same mechanism of action. We show that DFTD behaves as a reversible covalent inhibitor of eEF-2K with a two-step mechanism of inhibition: a fast initial binding step, followed by a slower reversible inactivation step. Molecular docking suggests that a nitrile group of DFTD binds within 4.5 Å of the active site Cys146 to form a reversible thioimidate adduct. Because Cys146 is not conserved amongst other related kinases, targeting this residue holds promise for the development of selective covalent inhibitors of eEF-2K.
© 2014 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  cancer; covalent inhibitors; drug discovery; eEF-2 kinase; nitriles

Mesh:

Substances:

Year:  2014        PMID: 25224652      PMCID: PMC6482285          DOI: 10.1002/cbic.201402321

Source DB:  PubMed          Journal:  Chembiochem        ISSN: 1439-4227            Impact factor:   3.164


  7 in total

1.  Solution Structure of the Carboxy-Terminal Tandem Repeat Domain of Eukaryotic Elongation Factor 2 Kinase and Its Role in Substrate Recognition.

Authors:  Andrea Piserchio; Nathan Will; David H Giles; Fatlum Hajredini; Kevin N Dalby; Ranajeet Ghose
Journal:  J Mol Biol       Date:  2019-05-18       Impact factor: 5.469

2.  Structural Dynamics of the Activation of Elongation Factor 2 Kinase by Ca2+-Calmodulin.

Authors:  Nathan Will; Kwangwoon Lee; Fatlum Hajredini; David H Giles; Rinat R Abzalimov; Michael Clarkson; Kevin N Dalby; Ranajeet Ghose
Journal:  J Mol Biol       Date:  2018-05-22       Impact factor: 5.469

3.  Structure of the C-Terminal Helical Repeat Domain of Eukaryotic Elongation Factor 2 Kinase.

Authors:  Nathan Will; Andrea Piserchio; Isaac Snyder; Scarlet B Ferguson; David H Giles; Kevin N Dalby; Ranajeet Ghose
Journal:  Biochemistry       Date:  2016-09-14       Impact factor: 3.162

4.  The role of calcium in the interaction between calmodulin and a minimal functional construct of eukaryotic elongation factor 2 kinase.

Authors:  Kwangwoon Lee; Eric A Kumar; Kevin N Dalby; Ranajeet Ghose
Journal:  Protein Sci       Date:  2019-12       Impact factor: 6.725

5.  Target-Driven Design of a Coumarinyl Chalcone Scaffold Based Novel EF2 Kinase Inhibitor Suppresses Breast Cancer Growth In Vivo.

Authors:  Ferah Comert Onder; Nermin Kahraman; Esen Bellur Atici; Ali Cagir; Hakan Kandemir; Gizem Tatar; Tugba Taskin Tok; Goknur Kara; Bekir Karliga; Serdar Durdagi; Mehmet Ay; Bulent Ozpolat
Journal:  ACS Pharmacol Transl Sci       Date:  2021-03-30

6.  Structural dynamics of the complex of calmodulin with a minimal functional construct of eukaryotic elongation factor 2 kinase and the role of Thr348 autophosphorylation.

Authors:  Andrea Piserchio; Kimberly Long; Kwangwoon Lee; Eric A Kumar; Rinat Abzalimov; Kevin N Dalby; Ranajeet Ghose
Journal:  Protein Sci       Date:  2021-05-05       Impact factor: 6.993

7.  Using docking and alchemical free energy approach to determine the binding mechanism of eEF2K inhibitors and prioritizing the compound synthesis.

Authors:  Qiantao Wang; Ramakrishna Edupuganti; Clint D J Tavares; Kevin N Dalby; Pengyu Ren
Journal:  Front Mol Biosci       Date:  2015-03-19
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.